Abstract:411 Objectives: Acute kidney injury (AKI) often complicates treatment outcomes of hospitalized patients, which manifests as decreased kidney glomerular filtration and results in toxic chemicals accumulating in blood. The pathogenesis of many AKI conditions has implicated reactive oxygen species (ROS) as a major factor. Ongoing research has shown that nanomaterials are superior to their small molecule counterparts due to the ability to control their biodistribution and intrinsic scavenging abilities. We found that selenium-doped carbon quantum dots localize in the kidneys of mice and eliminate ROS to treat and prevent AKI. Methods: Carbon quantum dots with high antioxidant capacity were prepared by doping selenium (SeCQDs) through a hydrothermal treatment. PET imaging of SeCQDs was preformed to evaluate biodistribution using Zr-89 (half life: 78.4 h) after functionalizing with deferoxamine (DFO; 89Zr-DFO-SeCQDs). AKI was induced by intramuscular injection of 50% glycerol into the hindlimbs (8 mL/kg) as well as by intraperitoneal injection of cisplatin (20 mg/kg) in mice. An equivalent dose of amifostine, an FDA approved drug that acts through a similar mechanism for AKI treatment, was used to demonstrate the superiority of SeCQDs for AKI therapy. Results: SeCQDs were found to rapidly and exclusively accumulate in kidneys as the uptake was 25.37±4.51 %ID/g at 4 h post-injection (p.i.) following intravenous administration and up to 72 h p.i. (20.47 %ID/g) using PET imaging (n=3). Blood serum creatinine (CRE) and blood urea nitrogen (BUN) as well as H&E staining of kidney tissue were used to validate therapeutic effects in the AKI models. Therapeutic doses of SeCQDs were found to be 1 µg per mouse for AKI induced using 50% glycerol. Serum CRE and BUN were markedly lower for SeCQDs (0.38±0.08 and 44.2±11.7 mg/dL, respectively) compared to PBS negative controls (1.76±0.42 and 169.2±55.1 mg/dL, respectively) (n=5 for all groups). Moreover, cisplatin-induced AKI was prevented by administering 50 µg of SeCQDs per mouse as determined by serum CRE and BUN for SeCQDs (0.5±0.07 and 93.4±53.3 mg/dL, respectively) compared to PBS negative controls (2.24±0.4 and 199.2±36.4 mg/dL, respectively) (n=5 for all groups). Amifostine at an equivalent dose in each AKI model (based on selenium and sulfur composition) was ineffective to treat either glycerol- (BUN: 129.4±45 mg/dL, CRE: 1.06±0.4 mg/dL) or cisplatin-induced AKI (BUN: 174±24.3 mg/dL, CRE: 2±0.59 mg/dL) (n=5 for all groups). Conclusion: PET imaging elucidated that SeCQDs predominately accumulate in kidneys for as long as 72 h. The high renal accumulation of SeCQDs proved a highly effective therapy for the treatment of AKI induced using 50% glycerol and prevention of AKI from cisplatin due to its antioxidant properties. In the same animal models, amifostine was unsuccessful in AKI treatment and demonstrates the promise of utilizing nanomaterials over small molecule drugs to treat kidney diseases.

Amorphous Nano-Selenium Quantum Dots Prevent Pulmonary Arterial Hypertension Through Recoupling Endothelial Nitric Oxide Synthase

Amorphous nano-selenium quantum dots improve endothelial dysfunction in rats and prevent atherosclerosis in mice through Na+/H+ exchanger 1 inhibition

Amorphous Selenium Nanoparticles Improve Vascular Function in Rats With Chronic Isocarbophos Poisoning via Inhibiting the Apoptosis of Vascular Endothelial Cells

Anti-Oxidant and Anti-Endothelial Dysfunctional Properties of Nano-Selenium in Vitro and in Vivo of Hyperhomocysteinemic Rats

Comparison of Selenium Nanoparticles and Sodium Selenite on the Alleviation of Early Atherosclerosis by Inhibiting Endothelial Dysfunction and Inflammation in Apolipoprotein E-Deficient Mice

A new application of nano-selenium: rescue of CK2 and mitochondria from oxidative stress to prevent cardiac hypertrophy

Hydrogen Sulfide Improves Endothelial Dysfunction in Hypertension by Activating Peroxisome Proliferator-Activated Receptor Delta/endothelial Nitric Oxide Synthase Signaling.

Selenium Supplementation Protects Against Arsenic-Trioxide-Induced Cardiotoxicity Via Reducing Oxidative Stress and Inflammation Through Increasing NAD+ Pool

Biogenic selenium nanoparticles synthesized by Lactobacillus casei ATCC 393 alleviate diquat-induced intestinal barrier dysfunction in C57BL/6 mice through their antioxidant activity.

Selenium nanoparticles alleviate hyperlipidemia and vascular injury in ApoE-deficient mice by regulating cholesterol metabolism and reducing oxidative stress

Selenium Nanoparticles Inhibit the Formation of Atherosclerosis in Apolipoprotein E Deficient Mice by Alleviating Hyperlipidemia and Oxidative Stress.

Preparation, characterization, and antioxidant and antiapoptotic activities of biosynthesized nano‐selenium by yak-derived Bacillus cereus and chitosan-encapsulated chemically synthesized nano‐selenium

Selenium supplementation elevated SELENBP1 to inhibit fibroblast activation in pulmonary arterial hypertension

Renal-Accumulating Selenium-Doped Carbon Quantum Dots Treat Acute Kidney Injury in Mice

Differential effects of organic and inorganic selenium compounds on adenosine deaminase activity and scavenger capacity in cerebral cortex slices of young rats

[Regulation of Endogenous Cystathionine-Gamma-lyase Gene Expression in High Pulmonary Flow by Nitric Oxide Precursor].

Synthesis of Sulfur-Selenium Doped Carbon Quantum Dots for Biological Imaging and Scavenging Reactive Oxygen Species

Elemental selenium at nano size (Nano-Se) as a potential chemopreventive agent with reduced risk of selenium toxicity: comparison with se-methylselenocysteine in mice

Influence of encapsulated sodium alginates and pectin on selenium nanoparticles and efficient cardioprotective effect in C2C12 cell line

ASSA13-03-38 Selenium Ameliorate Myocardial Fibrosis in Diabetic Rats Through Inhibiting GPx- ROS-Smad- CTGF Signalling Pathway

Selenium Speciation Determines the Angiogenesis Effect Through Regulating Selenoproteins to Trigger ROS-me Diate D Cell Apoptosis and Cell Cycle Arrest